Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial
暂无分享,去创建一个
K. Ruxrungtham | D. Berger | M. D. Béthune | F. Suter | M. Mcmurchie | J. Madruga | S. Spinosa‐Guzman | F. Tomaka | T. Vangeneugden | M. Pauw | D. Bánhegyi | D. Norris | E. Lefebvre | M. McMurchie | M. P. Béthune